Ascend Advanced Therapies Develops Proprietary Enhancers Boosting AAV Production Yields Up to 3-Fold
核心洞察
Ascend Advanced Therapies (搜索) has unveiled two proprietary manufacturing enhancers that increase adeno-associated virus (搜索) (AAV (搜索)) production yields by up to 3-fold while maintaining critical quality attributes.
The enhancers were tested at multiple scales using both Ascend's EpyQ® two-plasmid system and commercially available 3-plasmid systems, with no negative effects on quality parameters observed.
This breakthrough could enable twice as many patients to be treated per vector batch, reducing cost of goods and improving scalability for gene therapy (搜索) manufacturing.
Ascend Advanced Therapies (搜索) has announced breakthrough data demonstrating the performance of two proprietary manufacturing enhancers that deliver substantial increases in adeno-associated virus (搜索) (AAV (搜索)) production yields while maintaining critical quality attributes across batches. The development addresses one of the most persistent challenges in gene therapy (搜索) manufacturing and could significantly impact treatment accessibility and cost-effectiveness.
Enhanced Production Capabilities
The two enhancers were developed through collaborative research efforts and tested at multiple scales in HEK293 cells using both Ascend's EpyQ® two-plasmid AAV (搜索) Production System and a commercially available 3-plasmid system. Notably, no negative effects on quality parameters such as vg/cap ratio or mispackaged DNA were observed during testing.
Enhancer 1 demonstrated remarkable performance improvements, producing up to 3-fold more AAV (搜索) vector using EpyQ® in Ambr®15 systems and up to 1.7-fold more for the 3-plasmid system at Ambr®15 scale and in 2L bioreactors. Enhancer 2 showed similarly impressive results, producing up to 2.4-fold more AAV using the EpyQ® plasmid system at Ambr®15 scale, and up to 2.1-fold increases for Ambr®250 scale and 5L bioreactors.
The enhancer activity was further validated using customer plasmids, and the work has been replicated in experiments conducted by an external party interested in licensing the technology.
Clinical and Commercial Impact
"Improving AAV (搜索) productivity without compromising product quality is one of the most persistent challenges in gene therapy (搜索) manufacturing," said Dr. Markus Hörer, Chief Scientific Officer at Ascend Advanced Therapies (搜索). "This enhancer represents a meaningful step forward — not just for our internal platform, but for our partners who depend on scalable and reliable AAV manufacturing. This advancement could allow twice as many patients to be treated per vector batch, reducing cost of goods."
The implications extend beyond manufacturing efficiency. Dr. Alessandra Rispoli, Chief Executive Officer at Ascend Advanced Therapies (搜索), emphasized the broader impact: "By integrating this enhancer into our CMC offering, we enable our partners and customers to achieve higher yield, reduced cost per dose, and faster scalability, translating scientific innovation directly into patient and business impact."
Technology Integration and Licensing Plans
Ascend plans to integrate the enhancer technology across its process development and clinical manufacturing workflows, providing gene therapy (搜索) developers with access to more affordable, high-quality AAV (搜索) vectors. The company has announced plans to license the technology to the broader industry in the coming months.
The research findings are protected under patent WO2025087695A1 and build upon work originally published in Molecular Therapy – Methods and Clinical Development in December 2024. This intellectual property protection positions Ascend to capitalize on the commercial potential while expanding access to the technology through licensing agreements.
Company Background and Strategic Position
Ascend Advanced Therapies (搜索) operates as a gene-to-GMP contract development and manufacturing organization (CDMO) specializing in high-quality, cost-effective advanced therapy development and manufacturing. The company launched in early 2023 with the acquisition of Freeline Therapeutics (搜索) Munich manufacturing assets and development team, bringing AAV (搜索) development expertise dating from 1991.
The company has since expanded its footprint through strategic acquisitions, including GMP manufacturing assets from Beacon Therapeutics (搜索) in Alachua, Florida in early 2024, and a late 2024 alignment with ABL, Inc. (搜索) to expand development, manufacturing, and fill/finish capabilities for gene therapies, oncolytics, vaccines, and immunotherapies.